Research at Humanwell Healthcare (Group) Co. Ltd. has led to the identification of interleukin-1 receptor-associated kinase 4 (IRAK-4) inhibitors reported to be useful for the treatment of cancer and autoimmune diseases.

Incyte Corp. has patented bicyclic amines acting as cyclin-dependent kinase 12 (CDK12) inhibitors and reported to be useful for the treatment of cancer.

A Shandong Luye Pharmaceutical Co. Ltd. patent discloses serine/threonine-protein kinase PLK1 (STPK13) inhibitors reported to be useful for the treatment of cancer, neurodegeneration, autoimmune disease and viral infections.

Etnova Therapeutics Co. Ltd. has described gadolinium complexes reported to be useful for the treatment of stroke, ataxia, epilepsy, spinal cord injury, optic nerve injury, Alzheimer’s disease, Parkinson’s disease and Huntington’s disease, among others.

Yonsei University has divulged protein kinase inhibitors and/or degradation inducers reported to be useful for the treatment of cancer.

Chia Tai Tianqing Pharmaceutical Group Co. Ltd. has identified EGFR (HER1; erbB1) wild-type and/or mutant inhibitors reported to be useful for the treatment of cancer, particularly non-small-cell lung cancer (NSCLC).

Deciphera Pharmaceuticals LLC has synthesized heterocyclic compounds acting as eukaryotic translation initiation factor 2-α kinase 3 (PERK) and/or GCN2 inhibitors reported to be useful for the treatment of cancer and amyloidosis.

Suzhou Genhouse Bio Co. Ltd. has disclosed son of sevenless homolog 1 (SOS1) inhibitors reported to be useful for the treatment of cancer and more.

Scripps Research Institute has described nucleoside analogues acting as prodrugs reported to be useful for the treatment of SARS-CoV-2 infection (COVID-19).

Sortina Pharma AB has divulged sortilin (NT3; Gp95) antagonists reported to be useful for the treatment of cancer, Alzheimer's disease and Parkinson's disease.